Jounce Therapeutics, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$52.2M | −$91.1M | −$45.1M | $52.8M | −$31.3M | −$19.2M |
| Net income | −$50.9M | −$90.9M | −$43.8M | $56.8M | −$27.4M | −$16.4M |
| Total assets | $212.6M | $252.7M | $244.2M | $205.9M | $214.5M | $296.7M |
| Total liabilities | $29.4M | $28.9M | $32.9M | $31.3M | $110.3M | $129.6M |
| Equity | $183.1M | $223.8M | $211.3M | $174.6M | $104.1M | $167.1M |
| EPS (diluted) | $-0.99 | $-1.82 | $-1.24 | $1.66 | $-0.84 | — |
| Shares out. | 51.7M | 45.4M | 34.0M | 33.0M | 32.4M | 32.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −27.8%
- Return on assets
- −24.0%
- Return on capital (ROCE)
- −27.6%
- Liabilities / assets
- 13.8%
- Debt / equity
- 0.16×
- Book value / share
- $3.54
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- 5.75safe
- Accruals / assets
- −10.4%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 4, 2023
- Director / officer changeMar 30, 2023
- Entered a material agreement · Terminated a material agreement · Costs from exit or disposal · Regulation FD disclosureMar 27, 2023
- Other material eventMar 15, 2023
- Regulation FD disclosureMar 13, 2023
- Entered a material agreement · Costs from exit or disposal · Unregistered equity sale · Director / officer change · Regulation FD disclosureFeb 23, 2023
- Director / officer change · Other material eventJan 20, 2023
- Delisting / listing-standard noticeJan 5, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2024
- SC 13GFeb 9, 2024
- SC 13G/ACOWEN FINANCIAL PRODUCTS LLCFeb 2, 2024
- 15-12GMay 15, 2023
- 4FORM 4 SUBMISSIONMay 5, 2023
- 4FORM 4 SUBMISSIONMay 5, 2023
- 3FORM 3 SUBMISSIONMay 5, 2023
- SC 13D/AAMENDMENT NO. 4May 5, 2023
- EFFECTMay 4, 2023
- EFFECTMay 4, 2023
- 25-NSEMay 4, 2023
- 4FORM 4May 4, 2023
- 4FORM 4May 4, 2023
- 4FORM 4May 4, 2023
- 4FORM 4May 4, 2023
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.